A Phase II Study of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Ependymoma in Adults

Full Title

Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi Center Trial


Ependymomas are tumors of the brain or spinal cord. Carboplatin is a drug commonly used to treat several types of cancer. Bevacizumab is a drug that works by inhibiting the growth of the blood vessels that tumors need to grow and spread. In this study, investigators are assessing the safety and effectiveness of combination therapy with carboplatin and bevacizumab in patients with ependymoma of the brain or spinal cord.

Bevacizumab is approved for treating gliomas and other cancers, but its use in combination with carboplatin in patients with ependymoma is considered investigational.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of intracranial or spinal ependymoma or anaplastic ependymoma that has continued to grow despite at least one regimen of chemotherapy.
  • Patients must have recovered from the side effects of prior therapies. At least 4 weeks must have passed since completion of prior chemotherapy or major surgery and 6 weeks since any radiation therapy.
  • Patients may have had prior carboplatin but not bevacizumab.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Antonio Omuro at 212-639-7523.